A Reliable Research Partner in Life Science and Medicine

# Recombinant Cynomolgus PD-L1/B7-H1/CD274 Protein (Fc Tag)

Catalog Number: PKSQ050046

Note: Centrifuge before opening to ensure complete recovery of vial contents.

#### Description

**Species** Cynomolgus macaques

Source HEK293 Cells-derived Cynomolgus macaques PD-L1/B7-H1/CD274 protein Phe19-

Thr239, with an C-terminal Fc

Calculated MW52.4 kDaObserved MW73 kDaAccessionG7PSE7

**Bio-activity** Not validated for activity

### **Properties**

**Purity** > 95 % as determined by reducing SDS-PAGE.

**Endotoxin** < 1.0 EU per µg of the protein as determined by the LAL method.

**Storage** Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

**Shipping** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation** Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

**Reconstitution** Please refer to the printed manual for detailed information.

#### Data



> 95 % as determined by reducing SDS-PAGE.

#### Background

# **Elabscience®**

## Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.